EMEA-003502-PIP02-24 - paediatric investigation plan

mezagitamab

Key facts

• Active substance:
  mezagitamab
• Therapeutic area:
  Renal and urinary disorders
• Decision number:
  EMEA-003502-PIP02-24
• PIP number:
  EMEA-003502-PIP02-24
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of primary immunoglobulin A nephropathy
• Route(s) of administration:
  Subcutaneous use
• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  28/01/2025
• Compliance check done:
  No

Decision

EMEA-003502-PIP02-24 : EMA decision of 28 January 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for mezagitamab

Adopted Reference Number: EMADOC-1700519818-1860477